Subject: JAMA publish results of Statins cause cancer.

[Guest guest]

JAMA publish results of Statins cause cancer.

 

JAMA 1996 Jan 3;275(1):55-60Related Articles, Links

Comment in:

JAMA. 1996 Jan 3;275(1):67-9.

JAMA. 1996 May 15;275(19):1479-80; discussion 1481-2.

JAMA. 1996 May 15;275(19):1479; discussion 1481-2.

JAMA. 1996 May 15;275(19):1480-1; discussion 1481-2

JAMA. 1996 May 15;275(19):1480; discussion 1481-2.

JAMA. 1996 May 15;275(19):1480; discussion 1481-2.

JAMA. 1996 May 15;275(19):1481-2.

 

Carcinogenicity of lipid-lowering drugs.

Newman TB, Hulley SB.

Department of Laboratory Medicine, School of Medicine, University of

California, San Francisco, USA.

 

OBJECTIVE--To review the findings and implications of studies of

rodent carcinogenicity of lipid-lowering drugs.

 

DATA SOURCES--

Summaries of carcinogenicity studies published in the 1992 and 1994

Physicians' Desk Reference (PDR),

 

additional information obtained from the US Food and Drug

Administration, and published articles identified by computer

searching,bibliographies, and consultation with experts.

 

STUDY SAMPLE--We tabulated rodent carcinogenicity data from the 1994

PDR for all drugs listed as " hypolipidemics. "

 

For comparison, we selected a stratified random sample of

antihypertensive drugs.

We also reviewed methods and interpretation of carcinogenicity

studies in rodents and results of clinical trials in humans.

 

DATA SYNTHESIS--All members of the two most popular classes of lipid-

lowering drugs (the fibrates and the statins) cause cancer in

rodents,

in some cases at levels of animal exposure close to those

prescribed to humans.

 

CONCLUSIONS--Extrapolation of this evidence of carcinogenesis from

rodents to humans is a lengthy process.

Long-term clinical trials and careful postmarketing surveillance

during the next several decades are needed to determine whether

cholesterol- lowering drugs in fact do cause cancer in humans.

 

In the meantime, the results of experiments in animals

and humans suggest

that lipid-lowering drug treatment, especially with the fibrates

and statins, should be avoided

except in patients at high short-term risk of coronary heart disease.

_________________

JoAnn Guest

mrsjoguest

DietaryTipsForHBP

http://www.geocities.com/mrsjoguest/AIM.html